Tetrahydrobiopterin ( BH4 ) , a cofactor of nitric oxide synthase , might have a role in the treatment of portal hypertension ( PHT ) as its administration improves endothelial nitric oxide generation and hepatic endothelial dysfunction , and reduces portal pressure in experimental models of cirrhosis .